

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Shyamasundaran Kottilil	Position Title Staff Clinician		
eRA COMMONS USER NAME			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
MEDICAL COLLEGE, TRICHUR, INDIA	M.D.	1991	Medicine
MEMORIAL UNIVERSITY, CANADA	Ph.D.	1998	Immunology
BROWN UNIVERSITY	Residency	2000	Internal Medicine
NATIONAL INSTITUTES OF HEALTH	Fellowship	2003	Infectious Diseases

A. Positions and Honors

2003 TO PRESENT: Staff Clinician, Immunopathogenesis Section, Laboratory of Immunoregulation, NIAID

B. Selected peer-reviewed publications (in chronological order, past 2 years)

1. Kohli A, Zhang X, Murphy AA, Yang J, Donnelly R, Young H, Lempicki RA, **Kottilil S**. Differential transcriptome profiles and antiviral effect of Interferon- λ and Interferon α on HCV-infected and uninfected hepatoma cells. *J Vir. Hepat.* (2012) in press.
2. Osinusi A., Chary A, Winters MA, **Kottilil S**, Murphy AA, Polis MA, and Holodniy MIL28B Polymorphism is Not Associated with HCV Protease Diversity in HIV/HCV Co-infected Patients Treated with Pegylated Interferon and Ribavirin *J Med Virol.* (2012) in press.
3. Rasimas JJ, Katsounas A. Osinusi A. Raza H., Rosenstein D, McLaughlin M, Sachau W, O'Shea MA, Masur H, Murphy AA, Lempicki RA, Polis MA and **Kottilil S**. Class Prediction Analyses of Gene Expression Profiles Prior to Treatment Predicts Development of Psychiatric Adverse Events of HCV therapy Among HIV Co-infected individuals" *J AIDS* (2011) in press.
4. Zhang X, Daucher M, Baeza J, Kim C-W, **Kottilil S**. HIV-1 enhances HCV replication in an HCV continuous culture system expressing CD4 molecule by modulating IFN and TGF-family gene expression. *J. Med Virol* (2012) in press.
5. Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, **Kottilil S**. Dysregulation of innate immunity In HCV genotype 1 IL28B unfavorable genotype patients Impaired viral kinetics and therapeutic response. *Hepatology* 2012 Feb 13. doi: 10.1002/hep.25647 [Epub ahead of print]
6. Jones DM, Atoom AM, Zhang X, **Kottilil S**, Russell RS. A Genetic Interaction Between the Core and NS3 Proteins of Hepatitis C Virus is Essential for Production of Infectious Virus. *J Virol.* (2011) 85(23):12351-61.
7. Hadigan C, **Kottilil S**. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. *JAMA.* 2011 Jul 20;306(3):294-301.
8. Shah SR, Patel K, Marcellin P, Foster GR, Manns, M, **Kottilil S**, Healey L, Pulksteni E, Subramanian GM, McHutchison J, Sulkowski M., and Nelson DR. Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Hepatitis C Virus Genotype 3. *Clin Gastro Hepatol* (2011) 9(8):688-93.
9. Katsounas A, Trippler M, **Kottilil S**, Lempicki RA, Gerken G, Schlaak JF. Altered expression of SHIP, a Toll-like receptor pathway inhibitor, is associated with the severity of liver fibrosis in chronic hepatitis C virus infection. *J Infect Dis* (2011) (8):1181-5.
10. Sidique N, Kohli A, Shivakumar B, Migueles S, Subramanian GM, Naggie S, Polis MA, Masur H, **Kottilil S**. HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.. *J Acquir Immune Defic Syndr.* 2011 Oct 1;58(2):e38-40

11. Murphy AA, Herrmann E, Osinusi AO, Wu L, Sachau W, Lempicki RA, Yang J, Chung TL, Wood BJ, Haagmans BL, Kottlilil S, Polis MA.. Twice-weekly pegylated interferon- α -2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. *AIDS* (2011) 25(9):1179-1187.
12. Burbelo PD, Kovacs JA, Ching KH, Issa AT, Iadarola MJ, Murphy AA, Schlaak JF, Masur H, Polis MA and **Kottlilil S**. Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients. *J. Infect Dis* (2010) 202(6):894-8.
13. Natarajan V, **Kottlilil S**, Hazen A, Adelsberger J, Murphy AA, Polis MA, Kovacs JA. HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co-infected individuals. *J Med Virol.* (2010) 82(12):2032-7.
14. Chary A, Winters MA, **Kottlilil S**, Murphy AA, Polis MA, and Holodniy M. Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients. *J Infect Dis.* (2010) 202:889-93.
15. Broering R, Zhang X, **Kottlilil S**, Tripler M, Jiang M, Lu M, Gerken G, Schlaak JF. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. *Gut.* (2010) 59(8):1111-9.

C. Research Support

Select Research Support (all NIH Intramural Funds)

1. Lead Investigator for project #AI000886 titled "Role of Innate Immunity in the Initiation and Pathogenesis of HIV infection" (2001onwards).
2. Lead Investigator for project #AI000390 titled "The Therapeutic Strategies for the Management of HIV/HCV Co-infection" (2006 onwards).
3. NIH Bench to Bedside award (2011): Effect of Lysyl oxidase 2 monoclonal antibody on liver disease progression in HIV patients
4. NIH Bench to Bedside award (2011): Effect of Anti-PD-1/L1 monoclonal antibody to treat chronic Hepatitis B in HIV patients
5. NIH Bench to Bedside award (2011): Effect of CCR5 Blockade on liver disease progression in HIV patients
6. 2011: Hepatitis Research in HIV Patients (Principal Investigator, Office of AIDS Research Cycle 1 Award).
7. 2010: HIV, Hepatitis and Co-morbidities First-NIH Indo International Conference Award (Organizer, Office of AIDS Research Cycle 1 Award)
8. 2009: Ethnicity on Host Molecular factors that determine HCV Treatment Responses to Peg interferon-alpha and Ribavirin (Principal Investigator, Office of AIDS Research Cycle 3 Award)
9. 2009: Role of IFNAR2a on IFN Non-responsiveness of HIV/HCV-infected African Americans (Principal Investigator, Office of AIDS Research Cycle 2 Award)
10. 2009: Immunoregulation of HBV specific T cell responses in relation to the antiviral effect of HBV therapeutics in HBV mono and HIV/HBV co-infected subjects (Principal Investigator, NIAID DIR Supplemental Project Award)